Klotho Neurosciences, Inc. (KLTO)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Klotho Neurosciences, Inc. (KLTO) trades at $0.38 with AI Score 46/100 (Grade C). Klotho Neurosciences, Inc. is a biopharmaceutical company focused on developing gene therapies for neurodegenerative diseases, cancer, and cardiovascular disorders. Market cap: $20.08M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for KLTO: KLTO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates KLTO against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
KLTO: the 1 perspectives are evenly split.
How is this calculated? →Klotho Neurosciences, Inc. (KLTO) Healthcare & Pipeline Overview
Klotho Neurosciences, Inc., a biopharmaceutical company with a $20.08M market cap, focuses on developing gene therapies, including AMI-101 and AMI-202, for Alzheimer's disease and amyotrophic lateral sclerosis. Based in Omaha, Nebraska, the company operates in the high-risk, high-reward biotechnology sector, marked by intense competition and regulatory scrutiny.
What Is the Investment Thesis for KLTO?
Klotho Neurosciences, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on gene therapies for Alzheimer's disease and ALS addresses significant unmet medical needs, representing a substantial market opportunity if clinical trials are successful. The potential for AMI-101 and AMI-202 to demonstrate efficacy in treating these debilitating diseases could drive significant value creation. However, the company's negative ROE of -198.3% and negative Free Cash Flow of $-0.00B highlight the financial challenges and reliance on future funding. The company's small size and limited resources also pose risks in navigating the complex regulatory landscape and competing with larger, more established pharmaceutical companies. The high beta of 2.23 indicates significant volatility associated with the stock.
Based on FMP financials and quantitative analysis
KLTO Key Highlights
- Market Cap of $20.08M reflects the company's early stage and potential for growth.
- ROE of -198.3% indicates significant losses and the need for substantial capital investment.
- Free Cash Flow of $-0.00B highlights the company's reliance on external funding.
- Beta of 2.23 indicates high volatility compared to the overall market.
- Lead product candidates AMI-101 and AMI-202 target large and underserved markets in Alzheimer's disease and ALS.
Who Are KLTO's Competitors?
KLTO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BIIB Biogen Inc. | $212.58 | -1.64% | $31.39B | 78 |
| LLY Eli Lilly and Company | $1202.56 | -0.94% | $1.13T | 98 |
| IONS Ionis Pharmaceuticals, Inc. | $83.83 | +2.49% | $13.85B | 30 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are KLTO's Key Strengths?
- Novel gene therapy approach.
- Focus on unmet medical needs in Alzheimer's disease and ALS.
- Proprietary technology platform.
- Experienced management team.
What Are KLTO's Weaknesses?
- Limited financial resources.
- Small size and limited infrastructure.
- Early stage of development.
- High reliance on external funding.
What Could Drive KLTO Stock Higher?
- Initiation of Phase 1 clinical trials for AMI-101 in Q4 2026.
- Announcement of preclinical data for AMI-202 at a scientific conference in Q3 2026.
- Continued research and development of gene therapy platform.
- Pursuit of strategic partnerships and collaborations.
What Are the Key Risks for KLTO?
- Financial-distress signal — its Altman Z-Score of -0.00 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to secure additional funding.
- Negative clinical trial results for AMI-101 or AMI-202.
- Regulatory delays or rejection of AMI-101 or AMI-202.
- Competition from established pharmaceutical companies.
- High cash burn rate due to research and development expenses.
What Are the Growth Opportunities for KLTO?
- Expansion into New Therapeutic Areas: Klotho Neurosciences could leverage its expertise in gene therapy to expand its pipeline into other neurodegenerative disorders, such as Parkinson's disease or Huntington's disease. The market for Parkinson's disease therapeutics is projected to reach $5.6 billion by 2028, presenting a significant growth opportunity. This expansion would diversify the company's risk and increase its potential market reach, requiring additional research and development investment and strategic partnerships.
- Strategic Partnerships and Collaborations: Partnering with larger pharmaceutical companies or research institutions could provide Klotho Neurosciences with access to additional funding, expertise, and resources to accelerate the development and commercialization of its therapies. Collaborations can also facilitate access to new technologies and markets, enhancing the company's competitive position. Successful partnerships could significantly de-risk the company's pipeline and increase its long-term growth potential.
- Advancement of Clinical Trials: The successful completion of clinical trials for AMI-101 and AMI-202 is critical for the company's growth prospects. Positive clinical trial results could lead to regulatory approval and commercialization, generating significant revenue streams. The company needs to secure funding and manage clinical trials effectively to achieve these milestones. The Alzheimer's disease therapeutics market is projected to reach $13.7 billion by 2030, highlighting the potential revenue opportunity.
- Geographic Expansion: Expanding into international markets, particularly Europe and Asia, could provide Klotho Neurosciences with access to new patient populations and revenue streams. The company would need to navigate different regulatory environments and establish partnerships with local distributors to succeed in these markets. The global market for neurodegenerative disease therapeutics is expected to grow significantly in the coming years, driven by an aging global population.
- Development of Companion Diagnostics: Developing companion diagnostics to identify patients who are most likely to respond to AMI-101 and AMI-202 could improve the efficacy and adoption of these therapies. Companion diagnostics can help personalize treatment and reduce the risk of adverse events. The market for companion diagnostics is growing rapidly, driven by the increasing focus on personalized medicine. This strategy would require collaboration with diagnostic companies and investment in research and development.
What Opportunities Does KLTO Have?
- Strategic partnerships with larger pharmaceutical companies.
- Expansion into new therapeutic areas.
- Positive clinical trial results.
- Regulatory approval and commercialization of AMI-101 and AMI-202.
What Threats Does KLTO Face?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from established pharmaceutical companies.
- Lack of funding.
What Are KLTO's Competitive Advantages?
- Proprietary gene therapy technology.
- Intellectual property protection for AMI-101 and AMI-202.
- First-mover advantage in developing gene therapies for specific neurodegenerative disorders.
- Expertise in gene therapy research and development.
What Does KLTO Do?
Klotho Neurosciences, Inc., formerly known as Anew Medical, Inc., is a biopharmaceutical company dedicated to the discovery and development of innovative medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Founded with the mission to address unmet medical needs in these challenging therapeutic areas, the company changed its name in September 2024 to reflect its focus on the Klotho gene, which is associated with longevity and cognitive function. Klotho Neurosciences is based in Omaha, Nebraska. The company's lead product candidates are gene therapies: AMI-101, targeting Alzheimer's disease, and AMI-202, developed for amyotrophic lateral sclerosis (ALS). These therapies represent a novel approach to treating these diseases, aiming to modify the underlying genetic pathways involved in disease progression. As a relatively small company with 3 employees, Klotho Neurosciences operates in a competitive and highly regulated environment, requiring significant capital investment and navigating complex clinical trials to bring its therapies to market. The company's strategy centers on advancing its gene therapy candidates through preclinical and clinical development, seeking partnerships and collaborations to support its research and development efforts.
What Products and Services Does KLTO Offer?
- Develop gene therapies for neurodegenerative disorders.
- Focus on treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
- Research and develop AMI-101 for Alzheimer's disease.
- Research and develop AMI-202 for ALS.
- Conduct preclinical and clinical trials to evaluate the safety and efficacy of their therapies.
- Seek partnerships and collaborations to support research and development efforts.
How Does KLTO Make Money?
- Develop and commercialize gene therapies for specific diseases.
- Generate revenue through the sale of approved therapies.
- Seek funding through venture capital, grants, and partnerships.
- Out-license or sell their therapies to larger pharmaceutical companies.
What Industry Does KLTO Operate In?
Klotho Neurosciences operates within the biotechnology industry, a sector characterized by intense research and development, high regulatory hurdles, and significant investment requirements. The market for Alzheimer's disease and ALS therapies is substantial, driven by an aging population and the lack of effective treatments. The competitive landscape includes established pharmaceutical companies and other biotechnology firms developing novel therapies. Klotho Neurosciences' focus on gene therapy positions it within a cutting-edge area of the industry, but also exposes it to higher risks associated with novel technologies and regulatory uncertainty. The biotechnology industry is experiencing growth, fueled by advancements in genomics, personalized medicine, and gene editing technologies.
Who Are KLTO's Key Customers?
- Patients suffering from Alzheimer's disease.
- Patients suffering from amyotrophic lateral sclerosis (ALS).
- Healthcare providers who treat these patients.
- Pharmaceutical companies that may acquire or license their therapies.
KLTO Valuation & Market Position
With a $20.08M market cap, Klotho Neurosciences, Inc. sits in the micro-cap segment of the market. Relative to its peer group, KLTO's quantitative score of 46/100 is below the peer average of 73/100.
Key Financial Metrics
Return on assets is -37.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -52.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 19.74 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -93.1%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
Klotho Neurosciences, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.00 places it in the distress zone, a signal of elevated financial risk.
KLTO Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Novel gene therapy approach.
- Focus on unmet medical needs in Alzheimer's disease and ALS.
- Proprietary technology platform.
- Experienced management team.
Bear Case
- Limited financial resources.
- Small size and limited infrastructure.
- Early stage of development.
- High reliance on external funding.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
KLTO Latest News
No recent news available for KLTO.
KLTO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for KLTO.
Price Targets
Wall Street price target analysis for KLTO.
KLTO MoonshotScore
What does this score mean?
The MoonshotScore rates KLTO's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Joseph A. Sinkule
CEO
Joseph A. Sinkule serves as the CEO of Klotho Neurosciences, Inc. He brings experience in managing and leading small teams. His background includes overseeing the development of early-stage biopharmaceutical companies. He is responsible for guiding the strategic direction of Klotho Neurosciences and managing its day-to-day operations. Sinkule's expertise is crucial for navigating the challenges of the biotechnology industry and advancing the company's pipeline of gene therapy candidates.
Track Record: Under Joseph A. Sinkule's leadership, Klotho Neurosciences has focused on advancing its lead gene therapy product candidates, AMI-101 and AMI-202, through preclinical development. He has overseen the company's efforts to secure funding and establish partnerships to support its research and development activities. His strategic decisions have been instrumental in shaping the company's focus on gene therapies for neurodegenerative disorders.
KLTO Healthcare Stock FAQ
What does Klotho Neurosciences, Inc. do?
Klotho Neurosciences, Inc. is a biopharmaceutical company that develops gene therapies for the treatment of cancer, cardiovascular, and neurodegenerative disorders. The company's lead product candidates, AMI-101 and AMI-202, target Alzheimer's disease and amyotrophic lateral sclerosis (ALS), respectively. These therapies aim to modify the underlying genetic pathways involved in disease progression. Klotho Neurosciences focuses on advancing its gene therapy candidates through preclinical and clinical development, seeking partnerships and collaborations to support its research and development efforts. The company operates in the high-risk, high-reward biotechnology sector.
What do analysts say about KLTO stock?
As of May 10, 2026, there is limited analyst coverage of Klotho Neurosciences, Inc. (KLTO) due to its small market capitalization and early stage of development. Key valuation metrics, such as price-to-earnings ratio and price-to-sales ratio, are not meaningful due to the company's negative earnings and limited revenue. Growth considerations center on the successful development and commercialization of AMI-101 and AMI-202. The company's stock is subject to high volatility due to the inherent risks associated with biotechnology companies and the uncertainty surrounding clinical trial outcomes. Investors should conduct their own due diligence and consider their risk tolerance before investing in KLTO.
What are the main risks for KLTO?
Klotho Neurosciences faces several significant risks, including the potential for clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. The company's limited financial resources and small size also pose challenges in navigating the complex regulatory landscape and competing with larger, more established players. The high cash burn rate due to research and development expenses and the reliance on external funding further increase the company's financial risk. Negative clinical trial results for AMI-101 or AMI-202 could significantly impact the company's value and future prospects.
What are the key factors to evaluate for KLTO?
Klotho Neurosciences, Inc. (KLTO) holds an AI score of 46/100 (low). Not financial advice.
How frequently does KLTO data refresh on this page?
KLTO prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven KLTO's recent stock price performance?
Klotho Neurosciences, Inc. (KLTO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel gene therapy approach. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider KLTO overvalued or undervalued right now?
Valuing Klotho Neurosciences, Inc. (KLTO) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying KLTO?
Before investing in Klotho Neurosciences, Inc. (KLTO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of May 10, 2026.
- The biotechnology industry is subject to rapid changes and uncertainties.
- Clinical trial outcomes are inherently unpredictable.